Project description
Advancing vaccine development with novel adjuvant probes
The onset of climate change and the rise in harmful pathogens and diseases have underscored the critical need for enhanced vaccines and vaccine-related technologies to keep pace with increasingly adaptive viruses. The ERC-funded ADJUPROBE project aims to leverage a groundbreaking discovery to validate and capitalise on its dual synthetic technological tool. The project seeks to bolster production and testing capabilities, while devising strategies for enhanced technical development. Moreover, it aims to improve the efficiency of its adjuvant technology to surpass current options. Ultimately, the project will ready the technology for commercialisation, while safeguarding relevant intellectual properties and patents.
Objective
The goal of ADJUPROBE is to build upon a major discovery made within the ERC-2016-STG-716878 project to validate and valorise our dual synthetic technological tool, moving it forward to boost vaccine efficacy from technical development to commercialisation. We will exploit our lead adjuvant in further preclinical settings in terms of scaled-up production, functional validation, and additional vaccine trials in mice with clinically relevant antigens. In parallel, we will confirm and advance the innovation of our technology towards commercial exploitation by implementing a multifaceted valorisation plan supporting the technical development. The plan includes consolidation of intellectual property (IP) rights and IP position, engagement of pharma/biotech partners and investors, as well as verification of the potential of spin-off creation.
Our adjuvant technology based on a scalable semi-synthetic saponin has demonstrated its potential as a dual tool with superior performance to the approved, natural QS-21 adjuvant. These breakthroughs have been provisionally protected via a priority patent application and have also attracted the interest of important biotech/pharma companies. ADJUPROBE will provide decisive proof-of-concept for preclinical development and validation of our technological tool, including synthesis upscaling and confirmation of the superiority of our adjuvant lead in disease-related vaccines benchmarked against QS-21. Moreover, key valorisation outcomes based on successful implementation of our transference and commercialisation plan, such as advancing IPR protection and spin-off creation together with fruitful pharma and investor partnerships, will facilitate market entry and traction for ADJUPROBE in the near future.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.1.1 - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2023-POC
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
48160 DERIO VIZCAYA
Spain
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.